Creo Medical Limited
CREO.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.12 | 0.12 |
| FCF Yield | 27.33% | 0.00% | -11.72% | -4.35% |
| EV / EBITDA | -4.18 | 0.00 | -10.64 | -18.35 |
| Quality | ||||
| ROIC | -14.60% | 0.00% | -19.41% | -18.70% |
| Gross Margin | 45.45% | 0.00% | 47.37% | 51.66% |
| Cash Conversion Ratio | 0.91 | – | 1.11 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | 72.18% | 1,357.65% | 1,409.87% | 1,827.44% |
| Free Cash Flow Growth | 0.00% | 100.00% | -97.22% | 53.25% |
| Safety | ||||
| Net Debt / EBITDA | 1.72 | 0.00 | -0.37 | -0.57 |
| Interest Coverage | -100.00 | 0.00 | 0.00 | -39.33 |
| Efficiency | ||||
| Inventory Turnover | 0.38 | 0.00 | 0.94 | 0.90 |
| Cash Conversion Cycle | 109.09 | 0.00 | 93.49 | 130.92 |